OBJECTIVE: To describe gender-based differences in disease progression, treatment, and outcome among patients receiving highly active antiretroviral therapy (HAART) in South India. METHODS: Therapy-naïve patients initiating HAART between February 1996 and June 2006 at a tertiary HIV referral center in Chennai, South India, were analyzed using the YRG CARE HIV Observational Database. Patients with 1 year of follow-up after initiating HAART were examined to investigate immunological and clinical outcomes, including the development of adverse events to therapy and opportunistic infections. RESULTS: All previously therapy-naïve patients who initiated HAART with at least 1 year of follow-up (n = 1972) were analyzed. At enrollment into care, women had higher CD4 counts, lower hemoglobin, and higher body mass index (BMI) than their male counterparts (p < 0.05). At the time of initiating therapy, women had higher CD4 counts and lower hemoglobin (p < 0.05); women continued to have higher CD4 counts at 12 months (p < 0.05). After 1 year following HAART initiation, significantly more men developed tuberculosis and Pneumocystis jiroveci pneumonia (p < 0.05), more women experienced lactic acidosis and nausea, and more men developed immune reconstitution syndrome (p < 0.05). CONCLUSIONS: Significant physiological, immunological, and clinical differences exist between men and women initiating HAART in a resource-limited setting in South India. Future studies should examine whether clinical management strategies should be different for men and women in resource-limited settings.
OBJECTIVE: To describe gender-based differences in disease progression, treatment, and outcome among patients receiving highly active antiretroviral therapy (HAART) in South India. METHODS: Therapy-naïve patients initiating HAART between February 1996 and June 2006 at a tertiary HIV referral center in Chennai, South India, were analyzed using the YRG CARE HIV Observational Database. Patients with 1 year of follow-up after initiating HAART were examined to investigate immunological and clinical outcomes, including the development of adverse events to therapy and opportunistic infections. RESULTS: All previously therapy-naïve patients who initiated HAART with at least 1 year of follow-up (n = 1972) were analyzed. At enrollment into care, women had higher CD4 counts, lower hemoglobin, and higher body mass index (BMI) than their male counterparts (p < 0.05). At the time of initiating therapy, women had higher CD4 counts and lower hemoglobin (p < 0.05); women continued to have higher CD4 counts at 12 months (p < 0.05). After 1 year following HAART initiation, significantly more men developed tuberculosis and Pneumocystis jiroveci pneumonia (p < 0.05), more women experienced lactic acidosis and nausea, and more men developed immune reconstitution syndrome (p < 0.05). CONCLUSIONS: Significant physiological, immunological, and clinical differences exist between men and women initiating HAART in a resource-limited setting in South India. Future studies should examine whether clinical management strategies should be different for men and women in resource-limited settings.
Authors: S Newmann; P Sarin; N Kumarasamy; E Amalraj; M Rogers; P Madhivanan; T Flanigan; S Cu-Uvin; S McGarvey; K Mayer; S Solomon Journal: Int J STD AIDS Date: 2000-04 Impact factor: 1.359
Authors: Lytt I Gardner; Scott D Holmberg; Janet Moore; Julia H Arnsten; Kenneth H Mayer; Anne Rompalo; Paula Schuman; Dawn K Smith Journal: J Acquir Immune Defic Syndr Date: 2002-01-01 Impact factor: 3.731
Authors: R R Gangakhedkar; M E Bentley; A D Divekar; D Gadkari; S M Mehendale; M E Shepherd; R C Bollinger; T C Quinn Journal: JAMA Date: 1997-12-17 Impact factor: 56.272
Authors: Antonia L Moore; Ole Kirk; Anne M Johnson; Christine Katlama; Anders Blaxhult; Manfred Dietrich; Robert Colebunders; Antonio Chiesi; Jens D Lungren; Andrew N Phillips Journal: J Acquir Immune Defic Syndr Date: 2003-04-01 Impact factor: 3.731
Authors: David Eisenman; Laura M Bogart; Chloe E Bird; Rebecca L Collins; Daniela Golinelli; Allen Fremont; Robin Beckman; William Cunningham Journal: AIDS Patient Care STDS Date: 2007-06 Impact factor: 5.078
Authors: N Kumarasamy; Suniti Solomon; Timothy P Flanigan; R Hemalatha; S P Thyagarajan; Kenneth H Mayer Journal: Clin Infect Dis Date: 2002-12-09 Impact factor: 9.079
Authors: Monica Gandhi; Peter Bacchetti; Paolo Miotti; Thomas C Quinn; Fulvia Veronese; Ruth M Greenblatt Journal: Clin Infect Dis Date: 2002-07-02 Impact factor: 9.079
Authors: Cynthia Firnhaber; Laura M Smeaton; Beatriz Grinsztejn; Umesh Lalloo; Sharla Faesen; Wadzanai Samaneka; Rosa Infante; Aadia Rana; Nagalingeswaran Kumarasamy; James Hakim; Thomas B Campbell Journal: HIV Clin Trials Date: 2015-05-15
Authors: Mhairi Maskew; Alana T Brennan; Daniel Westreich; Lynne McNamara; A Patrick MacPhail; Matthew P Fox Journal: J Womens Health (Larchmt) Date: 2013-01-25 Impact factor: 2.681
Authors: Amisha Patel; Sunitha Vishwanathan; Tiny Nair; C G Bahuleyan; V L Jayaprakash; Abigail Baldridge; Mark D Huffman; Dorairaj Prabhakaran; P P Mohanan Journal: Glob Heart Date: 2015-09-26
Authors: Aimalohi A Ahonkhai; Bolanle Banigbe; Juliet Adeola; Abdulkabir B Adegoke; Susan Regan; Ingrid V Bassett; Ifeoma Idigbe; Elena Losina; Prosper Okonkwo; Kenneth A Freedberg Journal: J Adolesc Health Date: 2016-06-18 Impact factor: 5.012